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Abstract
Background: Infection is a well acknowledged cause of stillbirths and may account for about half of all perinatal
deaths today, especially in developing countries. This review presents the impact of interventions targeting various
important infections during pregnancy on stillbirth or perinatal mortality.
Methods: We undertook a systematic review including all relevant literature on interventions dealing with
infections during pregnancy for assessment of effects on stillbirths or perinatal mortality. The quality of the
evidence was assessed using the adapted Grading of Recommendations, Assessment, Development and Evaluation
(GRADE) approach by Child Health Epidemiology Reference Group (CHERG). For the outcome of interest, namely
stillbirth, we applied the rules developed by CHERG to recommend a final estimate for reduction in stillbirth for
input to the Lives Saved Tool (LiST) model.
Results: A total of 25 studies were included in the review. A random-effects meta-analysis of observational studies
of detection and treatment of syphilis during pregnancy showed a significant 80% reduction in stillbirths [Relative
risk (RR) = 0.20; 95% confidence interval (CI): 0.12 - 0.34) that is recommended for inclusion in the LiST model. Our
meta-analysis showed the malaria prevention interventions i.e. intermittent preventive treatment (IPTp) and
insecticide-treated mosquito nets (ITNs) can reduce stillbirths by 22%, however results were not statistically
significant (RR = 0.78; 95% CI: 0.59 – 1.03). For human immunodeficiency virus infection, a pooled analysis of 6
radomized controlled trials (RCTs) failed to show a statistically significant reduction in stillbirth with the use of
antiretroviral in pregnancy compared to placebo (RR = 0.93; 95% CI: 0.45 – 1.92). Similarly, pooled analysis
combining four studies for the treatment of bacterial vaginosis (3 for oral and 1 for vaginal antibiotic) failed to
yield a significant impact on perinatal mortality (OR = 0.88; 95% CI: 0.50 – 1.55).
Conclusions: The clearest evidence of impact in stillbirth reduction was found for adequate prevention and treatment
of syphilis infection and possibly malaria. At present, large gaps exist in the growing list of stillbirth risk factors, especially
those that are infection related. Potential causes of stillbirths including HIV and TORCH infections need to be
investigated further to help establish the role of prevention/treatment and its subsequent impact on stillbirth reduction.
Background
Stillbirth, defined as a newborn having no sign of life at
delivery, is one of the most common adverse outcomes
of pregnancy. About 3.2 million stillbirths occur world-
wide each year [1]. The highest overall figures of
stillbirths have been reported from countries in South-
East Asia and sub-Saharan Africa [1]. Globally, infection
is a leading cause of stillbirth and accounts for an esti-
mated half of all stillbirths today, especially in develop-
ing countries [2]. A notable association exists between
infection and gestational age. A review reported that the
earlier the fetal death during gestation, the more likely it
is to be caused by an infection [3]. For example, in one
study, 19% of fetal deaths less than 28 weeks were
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any medium, provided the original work is properly cited.associated with an infection, while only 2% of term still-
births were infection-related [4]. Direct infection, pla-
cental damage, and severe maternal illness are the most
commonly reported mechanisms by which infections
may cause stillbirths [5].
Among infections, various organisms have been impli-
cated as causing stillbirth, including bacteria, viruses, pro-
tozoa, helminthes and fungi [6]. Syphilis remains an
avoidable cause of infection related stillbirths Plasmodium
falciparum malaria has been associated with stillbirth espe-
cially in primigravidas owing to its high prevalence and
extensive placental damage [7]. TORCH infections, which
include Toxoplasmosis, Other (syphilis, varicella-zoster,
parvovirus B19), Rubella, Cytomegalovirus (CMV), and
Herpes infections, are infections during pregnancy that are
associated with congenital anomalies and possibly still-
births [8,9]. Most of the TORCH infections cause mild
maternal morbidity, but have serious fetal consequences
[8]. Periodontal disease is another important chronic infec-
tious disease of humans which is commonly present in
pregnancy [10]. It’s prevalence range from 35 to 100%
(especially gingivitis) during pregnancy [11]. The risk of
adverse pregnancy outcomes including preterm birth, fetal
growth restriction may be increased in women with period-
ontal disease [12-15]. This may be the result of systemic
inflammatory responses due to a persistent periodontal
infection, or periodontal disease may be a marker for infec-
tion elsewhere in the body [12,16]. Helminthiasis is infesta-
tion of the human body by parasitic worms [17]. Millions
of pregnant women globally are infected with intestinal
nematodes [18] which leads to chronic blood loss, and can
be a major cause of iron deficiency anemia in reproductive
age, which is a risk factor for adverse perinatal outcome
[19]. A more detailed description of background literature
on maternal infections during pregnancy and their associa-
tion with stillbirths is given in Additional File 1.
The objective of this review was to synthesize up-to-date
evidence on the role of diagnosis and management of
infections in pregnancy and their effects on stillbirth. This
paper is a part of series of papers reviewing the effect of
interventions to be included in the Live Saved Tool (LiST)
[20]. This process involves qualitative assessment of avail-
able evidence according to the Grading of Recommenda-
tions, Assessment, Development and Evaluation (GRADE)
approach and quantitative analysis based on rules devel-
oped by the Child Health Epidemiology Reference Group
(CHERG) [20,21]. More details about CHERG methods
and LiST are available in the methods section of this
paper and the CHERG methods paper [20].
Methods
Literature search
We searched all relevant literature on interventions
dealing with infections during pregnancy to quantify
their impact on stillbirths and perinatal mortality. The
last date of the search was February 1
st 2010. The fol-
lowing infections were included in this review: syphilis,
P. falciparum malaria, HIV, bacterial vaginosis, ascend-
ing bacterial infections (chorioamnionitis), asymptomatic
bacteriuria, periodontal disease, helminthiasis, and
TORCH infections. The databases searched included
PubMed, the Cochrane Library, The Lancet Series and
hand search of bibliographies of relevant reviews.
Experts were also contacted in the field for unpublished
data. The search strategy for different infections is given
in Additional File 2:
Selection (inclusion/exclusion criteria)
The study designs primarily considered were rando-
mized and quasi-randomized trials however observa-
tional studies were also considered where data were not
available from randomized trials. There was no restric-
tion on language or publication status. There were no
limits on gestational age at the time of enrolment in the
study. For IPTp (intermittent preventive treatment of
P. Falciparum), we sought studies that measured the
effect of at least 2-doses per pregnancy of IPTp with
sulfadoxine-pyrimethamine versus a placebo, indepen-
dent of Insecticide treated nets (ITNs). Trials that com-
pared 2-doses of IPTp to another drug (not a placebo)
were excluded, as were trials that assessed IPTp com-
pared to ITNs where the effect of IPTp against a pla-
cebo could not be isolated. For ITNs, we sought studies
that measured the effect of access to ITNs among preg-
nant women versus no ITNs on stillbirths. Trials that
compared ITNs to untreated nets were excluded, as
were trials that assessed ITNs plus IPTp where the
effect of ITNs against no mosquito net (placebo) could
not be isolated.
Data abstraction and validity assessment
Each study that satisfied the eligibility criteria was
included in the review. A standardized data extraction
sheet was used [20]. The data were abstracted for key
variables like; participants’ characteristics, sample size,
location, study design and limitations, description of
intervention and control groups.
The individual studies were graded according to
CHERG adaptation of GRADE criteria [20]. A study was
graded as that of ‘high’‘ moderate’‘ low’ or ‘very low’ qual-
ity based on strengths and limitations of the study.
Studies received an initial score of high if they were a
randomized or cluster randomized trial. The grade was
decreased one grade for each study design limitation. In
addition, studies reporting an intent-to-treat analysis or
with statistically significant strong levels of association
(>80% reduction) received 0.5-1 grade increases. Any
study with a final grade of very low was excluded. The
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assessed and graded according to the CHERG adaptation
of the GRADE technique [20]. This assessment was
based on three components: 1) the volume and consis-
tency of the evidence; 2) the size of the effect, or risk
ratio; and 3) the strength of the statistical evidence for an
association between the intervention and outcome, as
reflected by the p-value [20,21].
Quantitative data synthesis
We performed meta-analyses where data were available
from more than one study for an outcome. The primary
outcomes of interest were stillbirths and perinatal mor-
tality. The reason for including perinatal mortality as an
outcome was based on the fact most of the studies do
not report disaggregated data for stillbirths but do that
by combining stillbirths with early neonatal deaths (i.e.
perinatal mortality). This exercise is in accordance with
the basics of CHERG rules which take into account the
biological plausibility of the intervention and limitations
of measured outcomes [20]. For example studies may
not collect the outcome of interest (e.g., pneumonia
mortality) but may collect data on severity of disease
(e.g. hospital admission). CHERG rules will thus con-
sider a range of outcomes (where necessary) and choose
a point estimate which is the most conservative and
represent the expected effect of the intervention based
on biological plausibility [20].
We used dichotomous values for pooling the data,
except for insecticide-treated mosquito nets (ITNs)
where data were pooled by generic inverse variance
method of meta-analysis. The summary estimates were
described as relative risk (RR) or Odd ratios (OR) with
95 % confidence interval (CI). The assessment of statisti-
cal heterogeneity among trials pooled data was done by
visual inspection (i.e. the overlap of the confidence
intervals among the studies), Chi square (P-value) and I
2
values. An I
2 value greater than 50% was taken to repre-
sent substantial heterogeneity in the pooled data. In
case of substantial heterogeneity, causes were explored
by sensitivity analysis. A random effects model was used
for the meta-analysis in case of substantial heterogene-
ity. All the analyses were conducted using Review Man-
ager 5 [22]. We applied the CHERG Rules for Evidence
Review to recommend a final estimate for reduction in
stillbirth from interventions for a specific maternal
infection during pregnancy [20].
Results
A total of 1155 hits were identified from our search
strategies (Figure 1). After screening the titles and
abstracts, 84 studies were initially considered eligible.
We thoroughly reviewed the abstracts and full texts,
where available and 25 studies were selected for
inclusion in the meta-analyses (Additional file 3). Addi-
tional File 4 outlines the characteristics of included
studies.
Syphilis
No randomized trials were found for treatment of
syphilis and its effect on prevention on stillbirths.
However, a random-effects meta-analysis of 8 observa-
tion studies by Blencowe et al. in this supplement has
shown an estimated reduction of 80 % (RR 0.20, 95%
CI 0.12 - 0.34) in syphilis related stillbirths with use of
penicillin [23]. It is however important to note that
none of the included studies in this meta-analysis
made any attempt to control for systematic differences
between treated and untreated women (confounding).
For example women not attending antenatal clinic
and/ or not complying with complex penicillin treat-
ment regimens may differ in their risk profiles for still-
birth, preterm delivery and neonatal death from fully
compliant infected women.
Malaria
There were 6 randomized controlled trials that
addressed prevention of malaria during pregnancy by
IPTp or ITN. As the effects of IPTp and ITNs used dur-
ing pregnancy have similar causal pathways for prevent-
ing stillbirth, and as there is no evidence of a synergistic
effect between them [24], the data were pooled irrespec-
tive of method used. The combined results show 22%
reduction in stillbirths (RR = 0.78; 95% CI: 0.59 – 1.03)
(Figure 2). A subgroup analysis of three trials [25-27]
that evaluated the impact of IPTp with sulfadoxine-pyri-
methamine vs. placebo showed no effect on stillbirth
(RR = 0.96; 95% CI: 0.62 – 1.50; fixed model) or perina-
tal mortality (RR = 0.78; 95% CI: 0.52 – 1.17; fixed
model). Pooled results of three studies that used ITNs
in pregnancy yielded a statistically significant association
with reduced fetal loss (RR 0.67, 95% CI 0.47 to 0.97)
compared to controls.
HIV
Our pooled meta-analysis of 6 studies [28-33] failed to
show a statistically significant reduction in stillbirth when
the use of anti-retrovirals in pregnancy was compared to
control (RR 0.93 95% CI 0.45 – 1.92) (See Figure 3).
Bacterial vaginosis
Our pooled analysis combining four studies [34-37]
showed a non-significant impact of treatment of bacter-
ial vaginosis on perinatal mortality (OR 0.88 95% CI
0.50 – 1.55). Sub-group analysis showed similar results
with the use of oral (OR 0.96 95% CI 0.53 – 1.73) and
vaginal (OR 0.35 95% CI 0.05 – 2.52) antibiotics (Fig 4).
There are no data on Still Births.
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use of antibiotics for preterm premature rupture of mem-
brane (pPROM) and reports a statistically significant 43%
reduction in risk of chorioamnionitis (RR = 0.57; 95% CI:
0.37 – 0.86). There was however no impact on perinatal
mortality/or fetal death before discharge (RR = 0.90; 95%
CI: 0.74 – 1.10). Another Cochrane review by Flenady
and King [39] on antibiotics for PROM at or near term
showed no impact of antibiotics on chorioamnionitis (RR
= 0.60; 95% CI: 0.30 – 1.18) nor on perinatal mortality
(RR = 0.98; 95% CI: 0.14 – 6.89). There were no separate
data on stillbirth.
Asymptomatic bacteriuria
Studies have looked at the association between asympto-
matic bacteriuria during pregnancy and perinatal mor-
tality. In a study performed from 1972 to 1979,
pregnant women with asymptomatic bacteriuria had a
significantly higher perinatal mortality (64.9 vs. 15.6, p <
0.001) [40]. However, a more recent population-based
retrospective study by Sheiner et al. showed that
patients with asymptomatic bacteriuria, in whom anti-
biotic treatment was recommended, had similar perina-
tal mortality rates compared to women without
asymptomatic bacteriuria (1.5% vs. 1.4%, P = 0.707) [41]
Periodontal disease
While published data convincingly display a link
between periodontal disease and stillbirth incidence
[10,15,42-44], there is limited literature on interventions
for periodontal disease and impact on stillbirths. The
systematic review by Polyzos et al. [14] studied the
impact of periodontal care during pregnancy and found
a non-significant effect on abortions and stillbirths (OR
= 0.73; 95% CI: 0.41 to 1.31). In a recent randomized
controlled trial, 1082 pregnant women with periodontal
disease were allocated either to receive periodontal
treatment in mid-pregnancy or after delivery. There
were four unexplained stillbirths in the control group
Numberofstudiesidentified
(n=1155)
Recordsexcluded
(n=1071)
FullͲtextarticlesassessedfor
eligibility(n=84)
FullͲtextarticlesexcluded
(n=59)
Recordsscreened
(n=1155)
HIV=6 BacterialVaginosis:5 Malaria=6
StudiesincludedinthemetaͲ
analysis
(n=25)
Syphilis=8
Figure 1 Flow diagram showing identification of studies.
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Relativerisk
(fixed) Study Intervention Weight(%)
RelativeRisk
(95%CI)
Parise 1998i IPTp 7.13 1.20(0.42Ͳ3.43)
Total IPTpand ITNs 100.00 0.78(0.59Ͳ1.03)
Testforoveralleffectz=1.78p=0.0757
Testforheterogeneity:X2=1.76df=6p=0.9403,I2=0.00%
Parise 1998ii IPTp 6.51 0.99(0.33Ͳ2.97)
Shulman 1998 IPTp 26.10 0.90(0.52Ͳ1.56)
Shulman 1999 ITN 4.95 0.67 (0.19Ͳ2.36)
Njagi (+SP)2002 ITN 9.98 0.68(0.28Ͳ1.65)
Njagi (ͲSP)2002 ITN 16.35 0.64(0.32Ͳ1.27)
TerKuile2003 ITN 28.99 0.69(0.41Ͳ1.16)
Figure 2 Forest plot for meta-analysis of the effect of malaria prevention in pregnancy (IPTp and ITNs) used during first or second pregnancy on
preventing stillbirths.
Figure 3 Treatment of HIV in pregnancy: Any antiretroviral vs. placebo Outcome: Stillbirth.
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non-significant (P = 0.12) [45]. A meta-analysis on peri-
odontal care during pregnancy versus treatment after
birth based on two studies [13,45] has shown a 70% sig-
nificant reduction in stillbirth (RR = 0.30; 95% CI: 0.12
– 0.76) (Philippa Middleton, personal communication).
Helminthiasis
A recent study from Uganda on deworming during
pregnancy has shown no effect of treatment with alben-
dazole or praziquantel on incidence of stillbirths com-
pared to placebo [46]. Another open label, randomized
controlled trial from Uganda that compared ivermectin,
albendazole, combined ivermectin/albendazole com-
pared with placebo showed similar results (P = 0.13)
[47]. The Cochrane review by Haider et al. reported the
pooled effect of use of anti-helminthic therapy on peri-
natal mortality based on two RCTs [48,49] and showed
no overall effect (RR = 1.10; 95% CI: 0.55 – 2.22).
TORCH INFECTION: TOXOPLASMOSIS, OTHER (SYPHILIS,
VARICELLA-ZOSTER, PARVOVIRUS B19), RUBELLA,
CYTOMEGALOVIRUS (CMV), AND HERPES INFECTIONS
A case control study from Jordan reports that the pre-
sence of Toxoplasmosis gondii was significantly higher
in those with adverse pregnancy outcomes compared to
controls (54% vs. 12%, p<0.02) [50]
Maternal rubella has been implicated as a cause of
stillbirths [51]. In Guinea-Bissau, stillbirth rates were
increased 4- to 9-fold if the mother was infected with
rubella during her pregnancy [3].
Cytomegalovirus
A study from Australia [52] reported that 9% of blood
samples taken from stillbirths by cardiac puncture were
PCR positive for CMV. A recent study from Greece
using PCR, showed significantly increased levels of
CMV (16%) in the placentas of stillbirths compared to
controls (3%) [53].
Study or Subgroup
5.1.1 Oral antibiotics
McDonald 1997
NICHD MFMU 2000
Odendaal 2002
Subtotal (95% CI)
Total events
Heterogeneity: Chi² = 3.29, df = 2 (P = 0.19); I² = 39%
Test for overall effect: Z = 0.14 (P = 0.89)
5.1.2 Vaginal antibiotics
Lamont 2003
Subtotal (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Total (95% CI)
Total events
Heterogeneity: Chi² = 4.20, df = 3 (P = 0.24); I² = 29%
Test for overall effect: Z = 0.43 (P = 0.67)
Test for subgroup differences: Chi² = 0.91, df = 1 (P = 0.34), I² = 0%
Events
1
13
8
22
1
1
23
Total
242
952
136
1330
208
208
1538
Events
1
19
3
23
3
3
26
Total
238
965
133
1336
201
201
1537
Weight
4.2%
65.5%
22.0%
91.7%
8.3%
8.3%
100.0%
Peto, Fixed, 95% CI
0.98 [0.06, 15.77]
0.69 [0.34, 1.39]
2.51 [0.75, 8.38]
0.96 [0.53, 1.73]
0.35 [0.05, 2.52]
0.35 [0.05, 2.52]
0.88 [0.50, 1.55]
Treatment Control Peto Odds Ratio Peto Odds Ratio
Peto, Fixed, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 4 Treatment of bacterial vaginosis in pregnancy: Any antibiotic versus placebo/no Outcome: Perinatal death.
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a cause of fetal death [54]. However, Herpes simplex
viruses rarely, if ever, cause stillbirth, likely because the
virus rarely causes an intrauterine infection. Neonatal
infections are acquired during fetal passage through an
infected birth canal. There is a paucity of evidence with
regards to the significance of Herpes virus in causing
stillbirths. Also, whether treatment and prevention have
a significant positive impact on adverse pregnancy out-
comes remains elusive.
Tables 1 - 4 outline the quality grading of the overall
evidence of all the interventions considered in this
review and described below in the same order.
Discussion
Syphilis remains a major cause of avoidable perinatal
death in many countries despite being treatable, and
despite the WHO recommendation that all pregnant
women be tested as part of routine antenatal care. Most
studies report syphilis to have a relative risk of stillbirth
in the range of 2 to 5; however, a Tanzanian study
reported a relative risk of 18 for women with active
syphilis [55]. In some areas of sub-Saharan Africa, about
25% to 50% of all stillbirths were associated with syphilis
[56]. Syphilis also contributes to stillbirths in other areas
of the world including Russia, Asia and South America
[57]. The findings of a meta-analysis by Blencowe et al.
correlate with the above observations and shows that
treatment of syphilis during pregnancy can significantly
reduce syphilis related stillbirths by up to 80 % [23]. This
estimate has been recommended for inclusion in the
LiST model with a quality grade of ‘low’ (Table 1). The
overall evidence was graded as ‘low’ as all the included
studies in the meta-aalysis were observational studies.
Malaria in pregnancy is an important preventable
cause of maternal and perinatal morbidity and mortality
[7]. The WHO advocates a three-pronged approach to
control malaria in pregnancy that includes the use of
ITNs, IPTp and case management of parasitemia with
artemisin-based therapies, especially in areas where
malaria is endemic [58]. Our meta-analysis suggests that
malaria prevention interventions in pregnancy (IPTp or
ITNs) can reduce stillbirths by 22% in malaria endemic
countries (RR = 0.78; 95% CI: 0.59 – 1.03). While this
effect is only marginally significant (and thus graded as
that of ‘moderate’ quality in table 4), there is other evi-
dence to suggest that such interventions could be highly
effective in improving maternal and birth outcomes
[58-61]. This is supported by the fact that IPTp has
been shown to significantly reduce placental malaria, as
well as maternal anemia [60], which are associated with
adverse pregnancy outcome.
The pandemic of human immunodeficiency virus
(HIV) in pregnancy is one of the major health problems
today [63]. Maternal HIV infection may increase the
risk of stillbirth [64]. A study from Zambia has reported
an inverse relationship between decreasing CD4 cell
counts in HIV seropositive women and stillbirth
(P =0.000) [65]. Our pooled analysis however failed to
show a statistically significant reduction in stillbirth
when antiretrovirals for pregnant women were com-
pared to placebo (RR = 0.93; 95% CI 0.45 – 1.92) and
thus no recommendations have been made for LiST
regarding this intervention. Results of our review are
consistent with the results from a Cochrane Review by
Volmink et al [66]. Data was not pooled in this
Cochrane review however none of the six included trials
showed a significant impact of antiretrovirals in preg-
nancy on stillbirth [66]. Pooled analysis from a review
by Suksomboon et al. [67], that included five rando-
mized trials, showed a non-significant impact on still-
birth (RR=1·11 95% CI 95% 0·48- 2·56).
Bacterial vaginosis in pregnant women is common,
ranging from 14% to 21% in Western countries and
13.6–18% in Asian countries [68]. However, very few
perinatal deaths have been reported in relation to
maternal bacterial vaginosis [68]. Mc Donald reports a
non-significant association of the treatment of bacterial
vaginosis in pregnancy with reduction in perinatal mor-
tality [34]. Our meta-analysis of four studies (3 for oral
and 1 for vaginal antibiotic) failed to yield a significant
impact on perinatal mortality (Figure 4). Whether treat-
ment of bacterial vaginosis will reduce stillbirths is
unknown and would need to be validated by future
trials. Applying the CHERG Rules for Evidence Review,
studies included for bacterial vaginosis and perinatal
Table 1 Quality assessment of trials of interventions for infections (syphilis) in pregnancy
Quality Assessment Summary of Findings
Directness No of events
No of
studies
(ref)
Design Limitations Consistency Generalizability to
population of
interest
Generalizability to
intervention of
interest
Intervention Control Relative
Risk (95%
CI)
Syphilis and stillbirth: LOWoutcome specific quality
8 Observational
studies
none Some heterogeneity and
5 out of 8 studies show
benefit
Yes Yes Not available Not
available
0.20 (0.12
- 0.34)
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dence. Included studies had limitations, including a low
recruitment response and unclear allocation conceal-
ment. The evidence to date does not suggest any benefit
of screening and treating all pregnant women for
asymptomatic BV to prevent stillbirths. Although anti-
biotic treatment targeting bacterial vaginosis may be of
value in some women [37], further research needs to be
carried out to study the potential impact of antibiotics
on chorioamnionitis, which is a well-established risk fac-
tor for stillbirth [6].
There are very few RCTs that have looked at the
impact of periodontal care on stillbirth or perinatal mor-
tality, with most trials reporting preterm birth as an out-
come. A recent meta-analysis of periodontal care
suggests that there may be an impact on stillbirths
(Middleton P, 2010 personal communication), but needs
confirmation in further trials from developing countries.
This is an emerging area of research that needs more
studies.
There is very limited evidence of the impact of anti-
helminthic therapy on stillbirths. There has been a ten-
dency towards increased risk of stillbirths and perinatal
mortality that is non-significant based on RCTs [17].
Maternal deworming, however, does hold promise for
improving the health of pregnant women in endemic
areas, particularly in terms of alleviating risk of anemia
and subsequently the risk of adverse pregnancy out-
comes [18]. It is, therefore, recommended in specific,
situational contexts such as where soil associated hel-
minthiasis rates are high and iron-deficiency anemia
rates endemic [69].
TORCH infection is an important risk factor for still-
births [8]. However, the pathways which lead from
infectious risk factors to fetal death are, for the most
part, not well defined [70,71]. There is a dearth of good
quality evidence on association of treatment of TORCH
on stillbirth and we recommend further research to
study the associations of these infections with stillbirth
and perinatal mortality.
Table 2 Quality assessment of trials of the evidence for prevention in malaria in pregnancy (IPTp and ITNs) used
during first or second pregnancy for preventing stillbirths
Quality assessment Summary findings
Directness Intervention Control
No of
studies
Design Limitations Consistency of
results
Generalizability
to population
of interest
Generalizability
to intervention
of interest
Number
of
events
Denominator Number
of
events
Denominator RR
(95%
CI)
IPTp for preventing stillbirths:High outcome-specific quality
3 RCT Consistent X
2
for
heterogeneity
(2 df) = 0.23
High High 44 1,489 36 1,083 0.96
(0.62-
1.50)
ITNs for preventing stillbirths:High outcome-specific quality
4 CRCT Not
blinded
Consistent X
2
for
heterogeneity
(3 df) = 0.03
High High Unknown Unknown Unknown Unknown 0.67
(0.47-
0.97)
Effect of IPTp and ITNs combined on stillbirths :Moderate outcome-specific quality
7 RCT/
CRCT
Consistent X
2
for
heterogeneity
(6 df) = 1.76
High High Unknown Unknown Unknown Unknown 0.78
(0.59-
1.03)
RCT: Randomized controlled trial: CRCT: Community randomized controlled trial: RR: Relative risk: CI: Confidence Interval.
Table 3 Quality assessment of trials of interventions for infections (HIV) in pregnancy
Quality Assessment Summary of Findings
Directness No of events
No of
studies
(ref)
Design Limitations Consistency Generalizability
to population of
interest
Generalizability
to intervention
of interest
Intervention Control Relative Risk
(95% CI)
Any anti-retroviral use for HIV and stillbirth: MODERATEoutcome specific quality
6 RCTs none Some heterogeneity from
meta-analysis; 4 out of 8 data
sets showing benefit
Yes Yes 22 22 RR (fixed) = 0.93
(0.45 - 1.92)
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Page 8 of 12The review employs a comprehensive search strategy
thus increasing the chance of retrieving all relevant stu-
dies. Mainly randomized controlled and quasi rando-
mized trials have been considered that provide a high
quality level of evidence. It is however important to note
that data from interventional studies were scarce. A high
quality research agenda addressing the contribution of
infections to stillbirth, especially in developing countries,
is needed to reduce stillbirths worldwide. At present,
large gaps exist in the growing list of stillbirth risk fac-
tors, especially those that are infection related [72]. The
clearest evidence of impact on stillbirth prevention is
adequate prevention and treatment of infections such as
syphilis and possibly malaria. Other potential causes of
stillbirth including HIV, bacterial vaginosis, ascending
infections and TORCH infections need to be investigated
further to help establish the role of prevention/treatment
and its subsequent impact on stillbirth reduction [72].
Efficacious interventions exist for certain maternal infec-
tions and conditions for which the evidence of plausible
benefit is not very clear. Therefore, efforts need to be
geared to conduct high quality trials for us to ascertain
the full extent of the relation between interventions and
their potential to reduce stillbirths.
Conclusions
The clearest evidence of impact in stillbirth reduction is
adequate prevention and treatment of maternal infec-
tions such as syphilis and possibly malaria. At present,
large gaps exist in the growing list of stillbirth risk fac-
tors, especially those that are infection related.
Key Messages
A reduction of 80% is observed in the incidence of still-
births in pregnant women with syphilis receiving
penicillin.
Malaria prevention intervention in pregnancy through
IPTp and ITNs providemay reduce stillbirths by 22%
during the first or second pregnancy in areas of stable
P. falciparum malaria transmission.
More studies need to be conducted to determine the
effectiveness of interventions for diseases such as HIV,
ascending bacterial infections and TORCH infections for
reducing stillbirths.
Additional material
Additional File 1: A word document containing a review of
literature for specific infections related to stillbirths.
Additional File 2: A word document containing the basic search
strategies and terms used for specific infections..
Additional File 3: An excel file that contains the data extraction
sheet of studies included in the review.
Additional File 4: A word file that described the characteristics of
studies included in the main meta-analysis.
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